Project Grant R44AI115892

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Grant Program (CFDA 93.855), provides $304,629 to Lactiga US Inc. to support the preclinical development of LCTG-001, a human secretory IgA replacement therapy for patients with common variable immune deficiency (CVID). The funding will be used to develop a non-clinical intranasal pharmacokinetic profile and formulation framework for LCTG-001...

This Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) provides $350,000 to Cisterna Biologics, Inc. to develop a novel production and purification process for ultra-pure mRNA. The key objectives are to generate contaminant-free mRNA essential for high-dosage and frequent therapeutic applications, such as enzyme replacement and cancer immunotherapy. The approach involves developing...

This Project Grant, awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,165,276 to Indiana University Indianapolis to investigate a novel immunocytokine therapy for suppressing inhibitor formation in hemophilia patients. The key products and services to be delivered under this 2-year award include preclinical assessments of the F5111-IC immunocytokine in multiple small and large animal models of hemophilia...

The National Science Foundation awarded a $249,884 Project Grant to the Regents of the University of Minnesota under the NSF Technology, Innovation, and Partnerships federal grant program (CFDA 47.084) to develop a decentralized, on-demand production system for large volume parenteral solutions and medical fluids. The University will implement a proof-of-concept prototype capable of producing 100 L/hr of solutions such as electrolyte replacement, intravenous fluids, and dialysis mixtures on-site...

This $863,697 Project Grant from the National Institutes of Health's National Institute of General Medical Sciences will support Provenance Group Inc.'s efforts to efficiently synthesize full-length human Type I collagen with appropriate post-translational modifications at high yields. The company will demonstrate that the recombinant collagen resembles its native counterpart and generate highly productive strains expressing full-length human Type I collagen showing appropriate prolyl...

This Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) aims to develop foundational data science methods and a pipeline for efficient and exceptional monoclonal antibody (mAb) formulation. The $342,776 award to Rutgers, The State University, will fund a project focused on using artificial intelligence/machine learning (AI/ML) and...

This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) supports the development of a novel in-line biomanufacturing process analytical technology tool. The $302,417 award to Physical Sciences Inc. (PSI), in collaboration with the University of Massachusetts Lowell (UML), aims to enable real-time monitoring of biomolecules in large-scale bioreactors for gene therapy manufacturing. The technology...

The National Institute of General Medical Sciences (NIGMS) awarded a $599,409 Project Grant under the Biomedical Research and Research Training program (CFDA 93.859) to Opera Bioscience, Inc., a woman-owned small business located in Evanston, Illinois. The grant supports the development of a novel bacterial protein secretion platform to produce cost-effective recombinant proteins and growth factors for therapeutic applications. Specifically, Opera Bioscience proposes to adapt its existing...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) is focused on developing a scalable manufacturing process for producing designer red blood cells (RBCs) derived from induced pluripotent stem cells (iPSCs). The $568,264 award to SAFI Biotherapeutics Inc., a pre-clinical blood cell therapy company, aims to optimize the iPSC-derived RBC (iRBC) production and validate the performance of different iRBC...

Partillion Bioscience Corp. was awarded a $659,037 Project Grant from the National Institutes of Health's National Institute of General Medical Sciences to develop reagent products enabling high-throughput screening and selection of single cells based on secreted bio-products. Under the Biomedical Research and Research Training program (CFDA 93.859), Partillion plans to transition its lab-on-a-particle technology—highlighted as a 2020 SLAS Innovation Award winner—into the first reagent product...